-
a-ФАКТОР НЕКРОЗУ ПУХЛИНИ ЛЮДИНИ' >">
a-ФАКТОР НЕКРОЗУ ПУХЛИНИ ЛЮДИНИ" onerror="$(this).attr('src', 'data:image/svg+xml,%3Csvg xmlns=\'http://www.w3.org/2000/svg\' width=\'200\' height=\'200\' viewBox=\'0 0 200 200\'%3E%3Crect width=\'100%25\' height=\'100%25\' fill=\'%23eee\'%3E%3C/rect%3E%3Ctext x=\'50%25\' y=\'50%25\' dominant-baseline=\'middle\' text-anchor=\'middle\' fill=\'%23333333\' font-family=\'Helvetica\' font-size=\'20\' font-weight=\'bold\'%3ENo Pic%3C/text%3E%3C/svg%3E');" data-original="" src="" data-zoom="viewer" class="img-fluid" style="width: 150px; max-height: 200px; object-fit: cover;">
公开(公告)号：UA57726C2
公开(公告)日：2003-07-15
申请号：UA98094737
申请日：1997-02-10
Applicant: BASF AG
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68
Abstract: Описаніантитілалюдини, переважнорекомбінантніантитілалюдини, якіспецифічнозв’язують - факторнекрозупухлин (hTNF). Ціантитілавідрізняютьсявисокоюспорідненістюдо hTNF (наприклад, Кd= 10-8 Μабоменше), низькоюшвидкістюспадудлядисоціації hTNF (наприклад, Кoff = 10-3 с-1 абоменше) танейтралізуютьактивність hTNF in vivo та in vitro. Антитілозгідноз винаходомє антитіломповноїдовжиничиантиген-зв’язуючоючастиноюантитіла. Антитілачичастиниантитілзгідноз винаходомможутьбутивикористанідлявиявлення hTNF тадляінгібуванняактивності hTNF , наприкладу людини, якастраждаєвідзахворювання, приякомуактивність hTNF єзгубною. Винахідтакожвідноситьсядонуклеїновихкислот, векторівтаклітин-хазяївдляекспресіїрекомбінантнихантитіллюдинизгідноз винаходомтадоспособівсинтезурекомбінантнихантитіллюдини.
-
Patent Agency Ranking
公开(公告)号：SI9720020B
公开(公告)日：2001-12-31
申请号：SI9720020
申请日：1997-02-10
Applicant: BASF AG
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINNESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：NZ331579A
公开(公告)日：2001-06-29
申请号：NZ33157997
申请日：1997-02-10
Applicant: BASF AG
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumour necrosis factor a (hTNFa) are provided. These antibodies have high affinity for hTNFa ( Kd of 10-8 M or less), a slow off rate for hTNFa dissociation (Koff of 10-3 sec-1 or less) and neutralize hTNFa cytotoxicity in a standard in vitro L929 assay with an IC50 of 10-7M or less. The antibodies, or antibody portions may be useful for inhibiting hTNFa activity in a human subject suffering from a disorder in which hTNFa activity is detrimental. Such disorders include sepsis, autoimmune diseases, infectious diseases, transplant rejection, malignancy, pulmonary disorder, intestinal disorder, cardiac disorder and inflammatory bone disorders.
-
公开(公告)号：TR9801532T2
公开(公告)日：1998-11-23
申请号：TR9801532
申请日：1997-02-10
Applicant: BASF AG
Inventor： SALFELD JACHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MACGUINESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68
CPC classification number: C07K16/241 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , Y02A50/412 , Y10S424/81
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha(hTNFalpha) are disclosed. These antibodies have high affinity for hTNFalpha (e.g., Kd=10-8 M or less), a slow off rate for hTNFalpha dissociation (e.g., Koff=10-3sec-1 or less) and neutralize hTNFalpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFalpha and for inhibiting hTNFalpha activity, e.g., in a human subject suffering from a disorder in which hTNFalpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：NO983627L
公开(公告)日：1998-10-07
申请号：NO983627
申请日：1998-08-07
Applicant: BASF AG
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , HOOGENBOOM HENDRICUS R J M , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINNES BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C07K
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：NO983627A
公开(公告)日：1998-10-07
申请号：NO983627
申请日：1998-08-07
Applicant: BASF AG
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , HOOGENBOOM HENDRICUS R J M , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINNES BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C07K
CPC classification number: C07K16/241 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , Y02A50/412 , Y10S424/81
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha(hTNFalpha) are disclosed. These antibodies have high affinity for hTNFalpha (e.g., Kd=10-8 M or less), a slow off rate for hTNFalpha dissociation (e.g., Koff=10-3sec-1 or less) and neutralize hTNFalpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFalpha and for inhibiting hTNFalpha activity, e.g., in a human subject suffering from a disorder in which hTNFalpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
-
-
-
-
Search Results
26
records
(took 0.023 seconds)
